Gemcitabine and Epirubicin in Pancreatic Cancer
Author Information
Author(s): Eickhoff A, Martin W, Hartmann D, Eickhoff J C, Möhler M, Galle P R, Riemann J F, Jakobs R
Primary Institution: Klinikum Ludwigshafen gGmbH
Hypothesis
The study aimed to find the maximum-tolerated dose of epirubicin in combination with gemcitabine in pancreatic carcinoma and evaluate the antitumour activity and clinical benefit of this combination.
Conclusion
The combination of gemcitabine and epirubicin is well tolerated and shows promising clinical activity in patients with advanced pancreatic cancer.
Supporting Evidence
- The maximum-tolerated dose was found to be GEM 1000 mg/m² and EPI 45 mg/m².
- The median time to progression was 5.1 months and median survival time was 7.4 months.
- Overall response rate was 23% based on partial responses in 9 out of 40 patients.
- Median overall survival time for patients with tumor response was 12.6 months.
Takeaway
This study tested a new combination of two cancer drugs to see if they work better together for people with pancreatic cancer, and it looks like they do.
Methodology
The study was a phase I/II trial that involved dose escalation to determine the maximum-tolerated dose and assess safety and efficacy.
Limitations
The study had a small sample size and was limited to patients with unresectable pancreatic carcinoma.
Participant Demographics
{"age":"67.5 years (range 43–75)","gender":"40% female, 60% male","performance_status":{"≥60":"20%","70–80":"62.5%","90–100":"17.5%"},"disease_stage":{"stage III":"32%","stage IV":"68%"}}
Statistical Information
P-Value
0.01
Confidence Interval
95% CI: 5.1–9.9
Statistical Significance
p=0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website